Relafen 750, pharmacologically known as naproxen, represents a important case study from a pharmacological pharmacy standpoint. This exhibits its medicinal effect primarily by inhibiting the activity of cyclooxygenase (COX) enzymes, specifically COX-2, thereby decreasing prostaglandin formation. The targeted inhibition of COX-2, compared to older N